{"filing":{"accession_number":"0001213900-26-088040","cik":"0001611842","ticker":"PYPD","company_name":"PolyPid Ltd.","form":"6-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"ea0301528-6k_poly.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611842/000121390026088040/ea0301528-6k_poly.htm"},"events":[{"id":27043,"run_id":24613,"accession_number":"0001213900-26-088040","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is a press release disclosing Q2 2026 financial results (net loss of $7.8M for three months, $15.6M for six months) alongside material corporate developments including FDA NDA acceptance with Priority Review, a $320M partnership with Azurity Pharmaceuticals, and a PDUFA goal date of November 28, 2026. While the release bundles multiple material events, the primary disclosure vehicle is the earnings announcement with accompanying financial statements (balance sheet and income statement), making this an earnings_release. The material partnership and regulatory milestones are disclosed as corporate highlights within the earnings context.","company_name":"PolyPid Ltd.","ticker":"PYPD","filing_date":"2026-08-12","form":"6-K","submitted_at":null,"items":[{"id":28402,"accession_number":"0001213900-26-088040","item_number":"EX-99.1","item_title":"ea030152801ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release disclosing Q2 2026 financial results (net loss of $7.8M for three months, $15.6M for six months) alongside material corporate developments including FDA NDA acceptance with Priority Review, a $320M partnership with Azurity Pharmaceuticals, and a PDUFA goal date of November 28, 2026. While the release bundles multiple material events, the primary disclosure vehicle is the earnings announcement with accompanying financial statements (balance sheet and income statement), making this an earnings_release. The material partnership and regulatory milestones are disclosed as corporate highlights within the earnings context.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:35:38.529699+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28402,"accession_number":"0001213900-26-088040","item_number":"EX-99.1","item_title":"ea030152801ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release disclosing Q2 2026 financial results (net loss of $7.8M for three months, $15.6M for six months) alongside material corporate developments including FDA NDA acceptance with Priority Review, a $320M partnership with Azurity Pharmaceuticals, and a PDUFA goal date of November 28, 2026. While the release bundles multiple material events, the primary disclosure vehicle is the earnings announcement with accompanying financial statements (balance sheet and income statement), making this an earnings_release. The material partnership and regulatory milestones are disclosed as corporate highlights within the earnings context.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:35:38.529699+00:00","company_name":"PolyPid Ltd.","ticker":"PYPD","filing_date":"2026-08-12"}]}